

**Final - June 24, 2024**

**MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)**

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

June 26-28, 2024

**Wednesday, June 26, 2024**

<b>8:00</b>	<b>Welcome &amp; Introductions</b>	Dr. Keipp Talbot (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
<b>8:30</b>	<b>Respiratory Syncytial Virus Vaccines - Adult</b>	
	Introduction	Dr. Camille Kotton (ACIP, WG Chair)
	Abrysvo (Pfizer) safety and immunogenicity in non-pregnant adults aged 18-59 years	Dr. Iona Munjal (Pfizer)
	Arexvy (GSK) immunogenicity with a 24-month revaccination interval	Dr. Susan Gerber (GSK)
	mRESVIA (Moderna) season 2 safety and efficacy update	Dr. Rituparna Das (Moderna)
	Postmarketing safety updates: Vaccine Safety Datalink	Dr. James Donahue (Marshfield Clinic Research Institute)
	Evaluation of Guillain-Barre Syndrome (GBS) following RSV vaccination among adults 65 years and older	Dr. Patricia Lloyd (FDA)
<b>10:00</b>	<b>Break</b>	
<b>10:10</b>	<b>RSV Vaccines - Adult (continued)</b>	
	Observational RSV vaccine effectiveness	Dr. Diya Surie (CDC, NCIRD)
	Economic analysis of adult RSV vaccination	Dr. David Hutton (University of Michigan)
	Update to benefits and risks discussion	Dr. David Hutton (University of Michigan)
	Comparison of economic analyses of adult RSV vaccination	Dr. Ismael Ortega-Sanchez (CDC/NCIRD)
<b>11:30</b>	<b>Break</b>	
<b>11:40</b>	<b>RSV Vaccines - Adult (continued)</b>	
	Evidence to Recommendations	Dr. Michael Melgar (CDC/NCIRD), Lauren Roper (CDC/NCIRD), Dr. Amadea Britton (CDC/NCIRD)
	Clinical Considerations	Dr. Michael Melgar (CDC/NCIRD)
<b>1:05</b>	<b>Break</b>	
<b>1:50</b>	<b>Combined Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate, and Hepatitis B vaccine (Vaxelis®)</b>	
	Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	EtR and proposed recommendations: Use of Vaxelis among American Indian and Alaska Native Infants	Dr. Jennifer Collins (CDC/NCIRD)
	Updated VFC resolution	Dr. Jeanne Santoli (CDC/NCIRD)
<b>2:50</b>	<b>Break</b>	
<b>3:00</b>	<b>Public Comment</b>	
<b>3:20</b>	<b><u>VOTES</u></b>	
	Respiratory Syncytial Virus (RSV) Vaccines Votes	Dr. Michael Melgar (CDC/NCIRD)
	Vaxelis	Dr. Jennifer Collins (CDC/NCIRD)
	Vaxelis VFC	Dr. Jeanne Santoli (CDC/NCIRD)
<b>4:10</b>	<b>Break</b>	
<b>4:20</b>	<b>Chikungunya Vaccine</b>	
	Introduction	Dr. Wilbur Chen (ACIP, WG Chair)
	Update on chikungunya vaccines	Dr. Susan Hills (CDC/NCEZID)
	Epidemiology of chikungunya in U.S. territories and states	Dr. Susan Hills (CDC/NCEZID)
	Cost-effectiveness of use of live attenuated chikungunya vaccine among adults living in U.S. territories	Dr. Kelly Kilburn, Dr. Erin Staples (CDC/NCEZID)
	Next steps for Work Group	Dr. Susan Hills (CDC/NCEZID)
<b>5:20</b>	<b>Dengue Vaccines</b>	
	Dengvaxia discontinuation	Dr. Nicholas Bergren (Sanofi)
	Dengue vaccine updates	Dr. Joshua Wong (CDC/NCEZID)
<b>5:30</b>	<b>Recess</b>	

## Final - June 24, 2024

### Thursday, June 27, 2024

8:00	<b>Welcome &amp; Introductions</b>	Dr. Keipp Talbot (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC) <i>CDC, CMS, FDA, HRSA, IHS, ODP, NIH</i>
8:15	<b>Agency Updates</b>	
8:35	<b>COVID-19 Vaccine</b>	
	Introduction	Dr. Matt Daley (ACIP, WG Chair)
	COVID-19-associated hospitalizations	Dr. Fiona Havers (CDC/NCIRD)
	COVID-19 vaccine effectiveness update	Dr. Ruth Link-Gelles (CDC/NCIRD)
	Vaccine safety update for 2023-2024 COVID-19 vaccine	Dr. Jonathan Duffy (CDC/NCEZID)
	Economic analysis of COVID-19 vaccination	Dr. Lisa Prosser (University of Michigan)
	EtR for use of the 2024-2025 COVID-19 vaccine	Dr. Lakshmi Panagiotakopoulos (CDC/NCIRD)
	COVID-19 vaccine implementation	Dr. Shannon Stokley (CDC/NCIRD)
11:05	<b>Break</b>	
11:20	<b>Influenza Vaccines</b>	
	Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	Influenza A (H5N1) Update	Dr. Vivien Dugan (CDC/NCIRD)
12:00	<b>Break</b>	
1:00	<b>Influenza Vaccines (continued)</b>	
	WG Considerations and Proposed Recommendations	Dr. Lisa Grohskopf (CDC/NCIRD)
	Updated VFC resolution	Dr. Jeanne Santoli (CDC/NCIRD)
2:00	<b>Pneumococcal Vaccines</b>	
	Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	Economic analysis and public health impact of PCV21 use in adults	Dr. Charles Stoecker (Tulane University)
	Comparison of economic analysis on PCV21 use in adults	Dr. Andrew Leidner (CDC/NCIRD)
	Summary of WG Interpretation of EtR and policy options on PCV21 use in adults	Dr. Miwako Kobayashi (CDC/NCIRD)
	Clinical considerations for PCV21 use in adults	Dr. Miwako Kobayashi (CDC/NCIRD)
3:55	<b>Break</b>	
4:10	<b>Public Comment</b>	
4:30	<b><u>VOTES</u></b>	
	COVID-19	Dr. Megan Wallace (CDC/NCIRD)
	Pneumococcal	Dr. Miwako Kobayashi (CDC/NCIRD)
	Influenza	Dr. Lisa Grohskopf (CDC/NCIRD)
	Influenza VFC	Dr. Jeanne Santoli (CDC/NCIRD)
5:15	<b>Recess</b>	

### Friday, June 28, 2024

8:30	<b>Welcome &amp; Introductions</b>	Dr. Keipp Talbot (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:55	<b>Meningococcal Vaccines</b>	
	Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	Epidemiology Updates	Ms. Amy Rubis (CDC/NCIRD)
	GSK Pentavalent Vaccine Immunogenicity and Safety	Dr. Wendy Sohn (GSK)
	WG Considerations Regarding MenABCWY Vaccine and Discussion of Potential Risk Groups for MenB Vaccination	Dr. Sarah Schillie (CDC/NCIRD)
10:00	<b>Break</b>	
10:15	<b>Respiratory Syncytial Virus Vaccines - Maternal/Pediatric</b>	
	Introduction	Dr. Sarah Long (ACIP, WG Chair)
	Implementation and uptake of nirsevimab and maternal RSV vaccine	Dr. Shannon Stokley (CDC/NCIRD)
	Maternal RSV vaccine safety surveillance	Dr. Pedro Moro (CDC/NCEZID)
	Summary of effectiveness of nirsevimab in infants	Dr. Amanda Payne (CDC/NCIRD)
	Work Group considerations	Dr. Jefferson Jones, Dr. Katherine Fleming-Dutra (CDC/NCIRD)
11:40	<b>Human papillomavirus Vaccines</b>	
	Announcement of formation of an ACIP HPV vaccines work group	Dr. Oliver Brooks (ACIP, WG Chair)
11:50	<b>Adjourn</b>	

***Acronyms***

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
HPV	Human papillomavirus
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention
NCIRD	National Center for Immunization & Respiratory Diseases
NCEZID	National Center for Emerging and Zoonotic Diseases
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
RSV	Respiratory Syncytial Virus (RSV)
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
WG	Work Group
WHO	World Health Organization
VE	Vaccine Effectiveness